Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

BOTHELL, WA, and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). At two years, 30% of patients who had received OGX-011 with first-line chemotherapy were alive. OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%.

For comparison, published studies using a platinum-based regimen plus gemcitabine as first-line chemotherapy for advanced NSCLC reported median survivals of 8 to 11 months and one-year survival rates of 33% to 43%. Market approval for Avastin plus paclitaxel and carboplatin chemotherapy for NSCLC was based on results showing a median survival of 12.3 months compared to 10.3 months for patients treated with chemotherapy alone. Survival rates for Avastin plus chemotherapy versus chemotherapy alone were reported as 51% versus 44% at one year and 23% versus 15% at two years, respectively.

"The two-year survival rate of 30% in our Phase 1/2 NSCLC study compares favorably to the survival reported for Avastin plus paclitaxel and carboplatin chemotherapy," said Scott Cormack, president and CEO of OncoGenex. "These data remain consistent with our Phase 2 data in prostate cancer suggesting that OGX-011 when added to chemotherapy may improve survival by blocking the production of clusterin, the protein associated with treatment resistance in various cancers."

    Non-Small Cell Lung Cancer Phase 1/2 Study Design with Updated Results as
    of January 23, 2009

This single-arm, open-label study enrolled 81 patients with Stage IIIB (18 percent) or Stage IV (82 percent) NSCLC who were treated with OGX-011 in combination w
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... -- The Diabetes Research Institute (DRI), a Center of ... of Medicine, announced today that the first patient ... first time a novel transplant technique for insulin-producing ... I/II study builds upon decades of progress in ... step toward the development of the DRI BioHub, ...
(Date:8/26/2015)... Aug. 26, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... entity wholly owned by Mr. Yuen Kam, chairman of ... the outstanding shares (the "Shares") of  Excellent China Healthcare ...
(Date:8/26/2015)... MA (PRWEB) , ... August 26, 2015 , ... The ... for Boston adult stem cell technology start-up company Asymmetrex to share the ... the capabilities of a new biomarker for counting adult tissue stem cells. , With ...
(Date:8/25/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, ... the company as Chief Operating Officer. Winham, who brings more ... experience, will report directly to HLI,s CEO, J. Craig ... as COO, Winham will be responsible for managing all HLI ... facility operations. HLI currently has three locations in ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... note: Recently the Wisconsin Technology Network sat down ... Technology Council , to discuss the basic tenets of ... forth to help Wisconsins technology space grow. Read Part ... What are the biggest challenges the Wisconsin Technology Council ...
... are born with talent and everywhere it is in chains. ... fail Britain. Talent is 21st century wealth. This quotation is ... UK, in 1999. It opens chapter one of The Mismanagement ... British HR researchers Anthony Hesketh, Phillip Brown and Sara Williams. ...
... My fathers slow retreat in the face of Alzheimers Disease was ... was slow, at first, but gathered momentum over time. Independence turned ... fine physical shape for a man of 80, but his memory ... or two was gone. His body simply forgot how to function. ...
Cached Biology Technology:WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 2WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 4Talent Mismanagement 2Talent Mismanagement 3The passing of Ronald Reagan, and other Americans, is a reminder of the promise of stem-cell research 2
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... This release is available in German . , ... instead of acting straight away. However to be called a frog ... frogs are real winners at least from the point of ... terms of numbers frogs are superior to all the other amphibians, ...
... Ariz. Jan. 13, 2011 Genomic research could help ... cancer patients, according to a study by Genomic Health Inc. ... The drug, oxaliplatin, is widely used in colon cancer. It ... that are likely to recur. It is also used in ...
... bit of a Jekyll and Hyde relationship with mercury, ... National Laboratory have made a discovery that ultimately could ... known that microbes in aquatic environments make methylmercury, a ... they also know that nature and other types of ...
Cached Biology News:Inventions of evolution: What gives frogs a face 2TGen and Genomic Health Inc. discover genes affecting cancer drug 2Natural dissolved organic matter plays dual role in cycling of mercury 2
... mini incubation trays are disposable ... screen antigens that have been ... tray has eight 10.5 cm ... accommodate strips cut from blotted ...
... represents the state-of-the-art in permanent mounting ... permanent preservation of immunohistochemical organic insoluble ... Red, New Fuchsin, and any other ... tissue sections. Clarin can be used ...
... Gene Inspector can perform many sophisticated DNA analysis ... much more than just another sequence analysis product. ... suite of analyses to be performed each time ... custom style sheets which specify exactly how your ...
... Solid phase extraction through columns is a ... of applications. Typical applications are in DNA/RNA ... diagnostics, or compound purification in chemical or ... automated on the Genesis series instruments for ...
Biology Products: